Trevi Therapeutics is advancing its investigational oral therapy Haduvio for chronic cough associated with idiopathic pulmonary fibrosis [1, 2].
This development targets a significant unmet medical need for patients with idiopathic pulmonary fibrosis, or IPF, who suffer from persistent cough. By establishing a specialty platform, the company aims to create a clinical beachhead for the treatment of chronic cough [1, 5].
The New Haven, Connecticut-based company recently completed enrollment for its Phase 2b CORAL trial [3]. This milestone allows the firm to move toward larger-scale testing after achieving alignment with the U.S. Food and Drug Administration [4].
Trevi has mapped out two pivotal Phase III trials to further evaluate the efficacy of the oral nalbuphine ER therapy. The first Phase III trial was slated to begin in the second quarter of 2026 [4]. The second Phase III trial is scheduled to start during the second half of 2026 [4].
Financial stability remains a key component of the company's strategy as it moves into these expensive late-stage trials. Trevi projects that its current cash runway extends into 2030 [6].
In addition to its clinical progress, the company maintained its corporate reporting schedule this month. Trevi reported its second-quarter 2026 financial results and provided a corporate update on Aug. 6 [1].
“Trevi projects that its current cash runway extends into 2030.”
The transition to Phase III trials represents the final major hurdle before a drug can seek regulatory approval. With a projected cash runway through 2030, Trevi is positioned to fund these pivotal studies without immediate need for dilutive financing, provided the clinical data remains positive.
